NA15
SEC. 15 ACKNOWLEDGEMENT - E-MAILED
14/09/2025
Voltar para busca
Dado oficial do USPTO
ACCEL RESEARCH SITES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ACCEL RESEARCH SITES
ST13
US500000086955371Classe
35, 42, 45
Pedido
86955371
Registro
5435841
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
52
Atualização mais recente
15/09/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
35, 42, 45
Data de depósito
28/03/2016
Data de registro
03/04/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/12/2024
Última transação
15/09/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
701
Cadastro oficial
Principal Register
Primeiro uso
2015-06-00
Primeiro uso no comércio
2015-06-00
Código do desenho
4
Tipo de titular
16
Localização do titular
Lake Mary, FL
Examinador
GARCIA, CLAUDIA
Localização atual
Historical data usage
Titulares e representantes
Titulares
Clinical Research Holdings, LLC
Clinical Research Holdings, LLC
Representantes
Mark A. Wright McLane Middleton, P.A.
Classificação técnica
Classes Nice
Classe 35Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Business consulting and management in the field of clinical trials in all phases as it relates to pre-study document collection and reviewsite selectionvisits and auditssite complianceproject tracking and monitoring reportsnegotiation and administration of investigator grants and clinical trial budgets and contractsfinancial and management accountingdistributioncoordination and tracking of clinical trial products and materialsregulatory document processinglaboratory selection and coordination; Business consulting and management in the field of clinical trials in all phases as it relates to managing site and study-specific subject recruitment strategies and programs in the nature of contingency strategies and solutions to address specific project challenges; Business consulting and management in the field of clinical trials in all phases as it relates to managing the development of all study related documents and materials in the nature of study protocolscontractsbudgetsamendmentspaper and electronic case report formsinformed consent formssafety narrativespresentation posterstraining manuals; Business consulting and management in the field of clinical trials in all phases as it relates to managing all aspects of studydrug reconciliationinventory and distribution reports; Business management for all aspects of clinical trials in all phases as it relates to managing investigatorscoordinatorsmonitorstechniciansparticipants for compliance with clinical protocols and regulations; Business consulting and management in the field of clinical trials in all phases as it relates to management and compilation of computerized databases in the field of clinical trials for business purposes; Business consulting and management in the field of clinical trials in all phases as it relates to ethical reviewssubmitting clinical trial protocols to institutional review boards and independent ethics committees on behalf of medicalbiopharmaceutical and biotechnology companies to assist them with clinical trials; Statistical analysis and reporting services for business purposes in the field of clinical trials; Business project management in the field of clinical trials in all phases as it relates to organizing and conducting business meetings of clinical trial investigators; Business managementmanaging randomization logisticsin the pharmaceutical and biotechnological field for business purposes; Development and implementation of personnel recruitment and retention programs for investigatorscoordinatorsmonitorstechnicians and participants for use in clinical trials; Business consulting and management in the field of clinical trials in all phases as it relates to the administration of protocols involving volunteer research patients and the recruiting of such volunteer research patients; Providing data management services in the medicalpharmaceutical and biotechnological field for business purposes
Classe 42
Medical and scientific research consulting services for others in the field of designplanningimplementation of clinical trials in all phases; providing quality assurance services in the pharmaceutical and biotechnological industries
Classe 45
Regulatory affairsreviewing standards and practices to assure compliance with clinical trial laws and regulations; Providing independent review of clinical trials involving human subjectsreviewing research protocols and related information to ensure protection of the rights and welfare of human subjects of research
Publicações
Histórico de despachos e eventos da marca no USPTO.
52 publicações encontradas
15AK
REGISTERED - SEC. 15 ACKNOWLEDGED
14/09/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/09/2025
E15R
TEAS SECTION 15 RECEIVED
18/08/2025
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
19/12/2024
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
19/12/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
19/12/2024
ES8R
TEAS SECTION 8 RECEIVED
03/04/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/01/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
29/01/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
29/01/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
29/01/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
29/01/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
03/04/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/01/2018
PUBO
PUBLISHED FOR OPPOSITION
16/01/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/12/2017
ALIE
ASSIGNED TO LIE
06/12/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/11/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
09/11/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/11/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
09/11/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/11/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/10/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/10/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/10/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
19/10/2017
GNRT
NON-FINAL ACTION E-MAILED
19/10/2017
CNRT
NON-FINAL ACTION WRITTEN
19/10/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/09/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/09/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/09/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
24/08/2017
GNRT
NON-FINAL ACTION E-MAILED
24/08/2017
CNRT
NON-FINAL ACTION WRITTEN
24/08/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
02/08/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/08/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
02/08/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/08/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/02/2017
GNRT
NON-FINAL ACTION E-MAILED
06/02/2017
CNRT
NON-FINAL ACTION WRITTEN
06/02/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/01/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/01/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/01/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
15/07/2016
GNRT
NON-FINAL ACTION E-MAILED
15/07/2016
CNRT
NON-FINAL ACTION WRITTEN
15/07/2016
DOCK
ASSIGNED TO EXAMINER
11/07/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
31/03/2016
NWAP
NEW APPLICATION ENTERED
31/03/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ACCEL RESEARCH SITES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.